Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection
Beteiligte Einrichtungen
Abstract
Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.
Bibliografische Daten
Originalsprache | Englisch |
---|---|
ISSN | 2328-8957 |
DOIs | |
Status | Veröffentlicht - 2017 |
PubMed | 28948181 |
---|